| |
Overall
|
Biologic-naïve
|
1 prior biologic
|
≥ 2 prior biologics
|
|---|
|
N = 225
|
N = 43
|
N = 92
|
N = 90
|
|---|
|
6-month baseline
|
6-month follow-up
|
6-month baseline
|
6-month follow-up
|
6-month baseline
|
6-month follow-up
|
6-month baseline
|
6-month follow-up
|
|---|
|
5-ASA, n (%)
|
112 (49.8)
|
70 (31.1)
|
25 (58.1)
|
16 (37.2)
|
49 (53.3)
|
30 (32.6)
|
38 (42.2)
|
24 (26.7)
|
|
Immunomodulator, n (%)
|
68 (30.2)
|
21 (9.3)
|
3 (7.0)
|
4 (9.3)
|
31 (33.7)
|
14 (15.2)
|
34 (37.8)
|
3 (3.3)
|
|
Oral corticosteroids, n (%)a
|
148 (65.8)
|
93 (41.3)
|
32 (74.4)
|
10 (23.3)
|
56 (60.9)
|
39 (42.4)
|
60 (66.7)
|
44 (48.9)
|
|
Daily dose, mg/day, mean (SD)b
|
31.5 (16.2)
|
28.2 (13.5)
|
30.1 (18.2)
|
22.5 (17.9)
|
33.6 (19.7)
|
26.6 (14.1)
|
30.4 (10.6)
|
30.9 (11.3)
|
- Baseline was defined as the 6 months prior to index date. Follow-up period was 6 months following the index date
- 5-ASA, 5-aminosalicylates; n, number of patients in the specified category; N, number of patients in the treatment group; TNFi, tumour necrosis factor inhibitor
- aBased on pharmacy claims only
- bPrednisone equivalent
